Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.50 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.50 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20358062 | 0.92 | KMT2A (0.62) | HTTSMN1; SMN2LMNAKDM4ENPC1 | |
| SCHEMBL18373573 | 0.85 | KMT2A (0.74) | HTTSMN1; SMN2LMNAKDM4ENPC1 | |
| Iodide SCHEMBL20357984 | 0.85 | HTT (0.78) | HTTSMN1; SMN2LMNAKDM4ENPC1 | |
| Iodide SCHEMBL16563094 | 0.85 | HTT (1.00) | HTTSMN1; SMN2LMNAKDM4ENPC1 | |
| Iodide SCHEMBL16563078 | 0.85 | HTT (1.00) | HTTSMN1; SMN2LMNAKDM4ENPC1 | |
| SCHEMBL19601074 | 0.84 | MEN1 (0.67) | HTTSMN1; SMN2LMNAKDM4ENPC1 | |
| SCHEMBL18376992 | 0.83 | KMT2A (0.77) | HTTSMN1; SMN2LMNAKDM4ENPC1 | |
| Perchlorate SCHEMBL7698387 | 0.83 | KMT2A (0.84) | HTTSMN1; SMN2LMNAKDM4ENPC1 | |
| Perchlorate SCHEMBL6644167 | 0.83 | KMT2A (0.84) | HTTSMN1; SMN2LMNAKDM4ENPC1 | |
| Iodide SCHEMBL16563183 | 0.83 | HTT (0.96) | HTTSMN1; SMN2LMNAKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10563120-B2 | Electrochromic compounds and optical articles containing them | ESSILOR INTERNATIONAL (FR) | 2020-02-18 | — | — | US | disclosed |
| US-20180194995-A1 | ELECTROCHROMIC COMPOUNDS AND OPTICAL ARTICLES CONTAINING THEM | ESSILOR INTERNATIONAL (FR) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194995-A1 | ELECTROCHROMIC COMPOUNDS AND OPTICAL ARTICLES CONTAINING THEM | EYA2, EYA3, ALDH1A2 | CHRM1 77/4885ACHE 91/4885CHRM3 101/4885 |
| US-10563120-B2 | Electrochromic compounds and optical articles containing them | EYA2, EYA3, ALDH1A2 | CHRM1 77/4885ACHE 91/4885CHRM3 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.